0001179110-21-001566.txt : 20210210 0001179110-21-001566.hdr.sgml : 20210210 20210210211244 ACCESSION NUMBER: 0001179110-21-001566 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210208 FILED AS OF DATE: 20210210 DATE AS OF CHANGE: 20210210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Epstein David R CENTRAL INDEX KEY: 0001445826 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38586 FILM NUMBER: 21616297 MAIL ADDRESS: STREET 1: INTERNATIONAL FLAVORS & FRAGRANCES INC. STREET 2: 521 W. 57TH STREET CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rubius Therapeutics, Inc. CENTRAL INDEX KEY: 0001709401 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042688109 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-679-9600 MAIL ADDRESS: STREET 1: 399 BINNEY STREET, SUITE 300 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2021-02-08 0 0001709401 Rubius Therapeutics, Inc. RUBY 0001445826 Epstein David R C/O RUBIUS THERAPEUTICS, INC. 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2021-02-08 4 S 0 89233 14.8837 D 4726220 D Common Stock 2021-02-09 4 S 0 2100 14.8314 D 4724120 D Common Stock 2021-02-10 4 S 0 7404 14.7927 D 4716716 D The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $15.05, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.90, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.75 to $14.87, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Joanne M. Protano, Attorney-in-Fact 2021-02-10